Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01870440 · ClinicalTrials.gov registry record · Phase 4
TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema
A Phase 4 study, sponsored by Northern California Retina Vitreous Associates.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT01870440 is a Phase 4 study that has completed, run by Northern California Retina Vitreous Associates. The registered enrollment target is 10 participants.
The verdict
NCT01870440, a Phase 4 study, has completed, sponsored by Northern California Retina Vitreous Associates.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether an intravitreal dexamethasone implant (Ozurdex, Allergan) is effective to manage macular edema secondary to non-infectious uveitis.
Interventions
- DRUG Ozurdex Intravitreal Injection (0.7 mg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01870440
The ClinicalTrials.gov registry entry for NCT01870440 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northern California Retina Vitreous Associates, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ozurdex Intravitreal Injection (0.7 mg) is the first listed.
NCT01870440 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01870440 about?
NCT01870440 is a clinical study titled "TAHOE: Intravitreal Dexamethasone Implant (Ozurdex) for Uveitic Macular Edema". The purpose of this study is to determine whether an intravitreal dexamethasone implant (Ozurdex, Allergan) is effective to manage macular edema secondary to non-infectious uveitis.
What is the current status of trial NCT01870440?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2013-05. Estimated completion is 2015-02.
What interventions are being tested in trial NCT01870440?
The interventions under investigation include: Ozurdex Intravitreal Injection (0.7 mg) (DRUG).
Who is sponsoring clinical trial NCT01870440?
This trial is sponsored by Northern California Retina Vitreous Associates, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.